top of page
![](https://static.wixstatic.com/media/053d36_6b3e83efc7cb48ec9a4de12cd2cec761~mv2.jpg/v1/fill/w_1920,h_1631,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/053d36_6b3e83efc7cb48ec9a4de12cd2cec761~mv2.jpg)
![white_logo_transparent_background.png](https://static.wixstatic.com/media/053d36_e94e9aeb41a04f619047e5db5a449870~mv2.png/v1/fill/w_254,h_79,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/white_logo_transparent_background.png)
Main Achievements
-
Participation to worlwide submissions: > 20 drugs in 40 countries (US, EU, LATAM, Asia, MENA, etc)
-
Setting the CMC regulatory strategy
-
Preparing CMC parts of dossiers
-
Managing answer strategy to questions from health authorities
​​
-
Participation to meetings with:
-
Health Authorities: FDA (2), ANVISA (2)
-
Pharmacopeias: Ph. Eur. and USP
-
​​
-
Elaboration of a monographs with:
-
Ph. Eur.: for a drug substance
-
USP: for 2 drug products
-
​​
-
Set tools to facilitate:
-
Gap analysis
-
Authoring/Updates of dossiers
-
Handling of Q&A from authorities
-
![covers 11th for cep news_edited_edited_e](https://static.wixstatic.com/media/053d36_fe62f49ae1504bf689b498b9b0a2c418~mv2.jpg/v1/crop/x_0,y_17,w_286,h_377/fill/w_97,h_128,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/covers%2011th%20for%20cep%20news_edited_edited_e.jpg)
![](https://static.wixstatic.com/media/053d36_a0d64348df6e4af58aa05d77146c4b2b~mv2.png/v1/fill/w_225,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/053d36_a0d64348df6e4af58aa05d77146c4b2b~mv2.png)
![](https://static.wixstatic.com/media/053d36_0b68e1c7e3b34db9a5e2b1f9d8914d0a~mv2.png/v1/fill/w_377,h_90,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/053d36_0b68e1c7e3b34db9a5e2b1f9d8914d0a~mv2.png)
![Logo_edited_edited_edited.jpg](https://static.wixstatic.com/media/053d36_a59957ae8fe94969a4ef12143180b495~mv2.jpg/v1/crop/x_0,y_85,w_2684,h_714/fill/w_355,h_99,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/Logo_edited_edited_edited.jpg)
bottom of page